1212 related articles for article (PubMed ID: 12584368)
1. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
2. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
[TBL] [Abstract][Full Text] [Related]
3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
4. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
6. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
7. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
8. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
9. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
10. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
14. [Infliximab therapy for Crohn's disease anoperineal lesions].
Ouraghi A; Nieuviarts S; Mougenel JL; Allez M; Barthet M; Carbonnel F; Cosnes J; Gendre JP; Flourié B; Meurisse JJ; Quandalle P; Ernst O; Lemann M; Cortot A; Modigliani R; Colombel JF
Gastroenterol Clin Biol; 2001 Nov; 25(11):949-56. PubMed ID: 11845044
[TBL] [Abstract][Full Text] [Related]
15. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
16. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
17. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
18. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
19. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
